Bronchopulmonary Dysplasia — No Simple Solution

Publisher Website
Google Scholar
Abstract
Progress in the treatment of neonates with the respiratory distress syndrome has been one of the medical success stories of the past 15 years. During this time, the widespread use of glucocorticoids to accelerate lung maturation, surfactant therapy, and improved methods of ventilation have drastically improved the outlook for these infants, so that preterm infants with birth weights between 500 and 750 g now have at least a 50 percent chance of survival.1 Unfortunately, a chronic neonatal lung disease called bronchopulmonary dysplasia develops in half the infants who survive, posing a challenge for clinicians and researchers alike.When first described . . .